摘要
目的评价依折麦布治疗冠心病的临床效果。方法选取2022年1月—2023年1月兖矿新里程总医院收治的70例冠心病患者为研究对象。应用奇偶分组法将其分为参照组与试验组,各35例。参照组选择常规治疗方案,试验组在常规治疗的基础上联合应用依折麦布药物。对2组的颈动脉斑块情况、心功能指标、血脂代谢指标、主要不良心脏事件发生率进行评定。结果干预后,试验组颈动脉内膜中层厚度、斑块厚度、斑块数量分别为(1.19±0.13)mm、(1.75±0.17)mm、(3.21±0.23)个,均低于参照组的(1.47±0.21)mm、(1.95±0.21)mm、(3.70±0.14)个,差异有统计学意义(P<0.001)。试验组左室射血分数、心脏输出量、舒张早期峰值速度/舒张晚期峰值速度分别为(56.12±4.13)%、(4.83±0.17)L/(min·m^(2))、(1.13±0.10),均高于参照组的(50.26±4.21)%、(4.11±0.21)L/(min·m^(2))、(0.91±0.08),差异有统计学意义(P<0.001)。试验组高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)为(1.21±0.11)mmoL/L,高于参照组的(1.12±0.13)mmoL/L;低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)、甘油三酯(triglyceride,TG)分别为(2.71±0.14)mmoL/L、(2.50±0.19)mmoL/L,均低于参照组的(3.18±0.21)mmoL/L、(3.09±0.15)mmoL/L,差异有统计学意义(P<0.05)。2组主要不良心脏事件总发生率比较,差异无统计学意义(P>0.05)。结论依折麦布治疗冠心病利于帮助患者改善心功能,稳定血脂,减轻颈动脉斑块程度。
Objective To evaluate the clinical effect of ezetimibe in the treatment of coronary heart disease.Methods A total of 70 patients with coronary heart disease admitted to Yankuang New Journey General Hospital from January 2022 to January 2023 were selected as the study objects.They were divided into reference group and experimental group with 35 cases in each group by parity grouping method.The reference group was treated with conventional treatment,and the experimental group was treated with ezetimibe combined with conventional treatment.The carotid artery plaque status,cardiac function index,lipid metabolism index and incidence of major adverse cardiac events were evaluated in the 2 groups.Results After intervention,the carotid intima-media thickness,plaque thickness and plaque number of the experimental group were(1.19±0.13)mm,(1.75±0.17)mm and(3.21±0.23),respectively,which were lower than(1.47±0.21)mm,(1.95±0.21)mm and(3.70±0.14)of the reference group,the differences were statistically significant(P<0.001).The left ventricular ejection fraction,cardiac output,early diastolic peak velocity/late diastolic peak velocity of the experimental group were(56.12±4.13)%,(4.83±0.17)L/(min·m^(2))and(1.13±0.10),respectively,which were higher than(50.26±4.21)%,(4.11±0.21)L/(min·m^(2))and(0.91±0.08)of the reference group,the differences were statistically significant(P<0.001).The high density lipoprotein cholesterol(HDL-C)of the experimental group was(1.21±0.11)mmoL/L,which was higher than(1.12±0.13)mmoL/L of the reference group,low density lipoprotein cholesterol(LDL-C)and triglyceride(TG)were(2.71±0.14)mmoL/L and(2.50±0.19)mmoL/L,respectively,which were lower than(3.18±0.21)mmoL/L and(3.09±0.15)mmoL/L of the reference group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of major adverse cardiac events between the two groups(P>0.05).Conclusion Ezetimibe can help patients improve cardiac function,stabilize blood lipids,and reduce carotid artery plaque in the treatment of coronary heart disease.
作者
李铮
徐林
LI Zheng;XU Lin(Department of Cardiology,Yankuang New Journey General Hospital,Zoucheng Shandong 273500,China)
出处
《中国卫生标准管理》
2025年第1期116-119,共4页
China Health Standard Management
关键词
冠心病
依折麦布
血脂水平
心功能
主要不良心脏事件
颈动脉斑块
coronary heart disease
ezetimibe
blood lipid levels
cardiac function
major adverse cardiac events
carotid artery plaque
